| In millions, except per share items | Jun-30-22 | Jun-30-21 | Jun-30-20 | Jun-30-19 | Jun-30-18 | Jun-30-17 | Jun-30-16 | Jun-30-15 |
| | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K |
| Revenues: |
| Infectious Disease | | | | | 17.7 | | | |
| Contract manufacturing revenue | | | | | 19.8 | 17.4 | | |
| Respiratory/Allergy/Cough/Cold | | | | | 25.3 | | | |
| Analgesic | | | | | 3.8 | | | |
| Other | | | | | 618.0 | 615.9 | | |
| Total revenues | 340.6 | 478.8 | 545.7 | 655.4 | 684.6 | 633.3 | 542.5 | 406.8 |
| Revenue growth [+] | -28.9% | -12.3% | -16.7% | -4.3% | 8.1% | 16.7% | 33.3% | 48.6% |
| Contract manufacturing revenue | | | | | 13.7% | | | |
| Cost of goods sold | 12.9 | 24.9 | 32.0 | 32.2 | 32.1 | 300.0 | 237.4 | 100.3 |
| Gross profit | 327.6 | 453.9 | 513.7 | 623.2 | 652.4 | 333.3 | 305.1 | 306.5 |
| Gross margin | 96.2% | 94.8% | 94.1% | 95.1% | 95.3% | 52.6% | 56.2% | 75.3% |
| Selling, general and administrative | 81.0 | 68.1 | 79.5 | 87.6 | 82.2 | 73.5 | 68.3 | 45.2 |
| Research and development | 22.4 | 24.2 | 30.0 | 38.8 | 29.2 | 42.1 | 45.1 | 30.3 |
| Other operating expenses | 294.5 | 378.3 | 348.5 | 379.6 | 363.7 | 36.1 | 42.2 | 0.1 |
| EBITDA [+] | -36.0 | 31.2 | 112.1 | 172.7 | 232.4 | 237.0 | 182.9 | 236.4 |
| EBITDA growth | -215.4% | -72.2% | -35.1% | -25.7% | -1.9% | 29.5% | -22.6% | 151.3% |
| EBITDA margin | -10.6% | 6.5% | 20.5% | 26.4% | 34.0% | 37.4% | 33.7% | 58.1% |
| Depreciation | 21.4 | 22.9 | 24.3 | 23.4 | 22.4 | 21.7 | 13.9 | 5.4 |
| EBITA | -57.3 | 8.2 | 87.8 | 149.4 | 210.0 | 215.3 | 169.0 | 230.9 |
| EBITA margin | -16.8% | 1.7% | 16.1% | 22.8% | 30.7% | 34.0% | 31.2% | 56.8% |
| Amortization of intangibles | 12.9 | 24.9 | 32.0 | 32.2 | 32.7 | 33.6 | 19.5 | 0.1 |
| EBIT [+] | -70.2 | -16.7 | 55.8 | 117.2 | 177.3 | 181.7 | 149.5 | 230.8 |
| EBIT growth | 321.5% | -129.9% | -52.4% | -33.9% | -2.4% | 21.5% | -35.2% | 162.0% |
| EBIT margin | -20.6% | -3.5% | 10.2% | 17.9% | 25.9% | 28.7% | 27.6% | 56.7% |
| Non-recurring items [+] | 106.1 | 220.6 | 36.2 | 379.5 | 47.6 | 95.2 | 18.8 | 4.3 |
| Asset impairment | 103.3 | 216.6 | 34.4 | 375.4 | 25.0 | 88.1 | 8.0 | |
| Loss (gain) on sale of assets | | | | | 15.5 | | | |
| Legal settlement | | | | | | -4.0 | -23.6 | |
| Interest expense, net [+] | 57.8 | 53.6 | 65.2 | 81.5 | 80.9 | 85.7 | 65.6 | -0.9 |
| Interest expense | 58.0 | 53.8 | 66.8 | 84.6 | 85.6 | 89.4 | 65.9 | 0.2 |
| Interest income | 0.2 | 0.2 | 1.6 | 3.2 | 4.8 | 3.8 | 0.4 | 1.1 |
| Other income (expense), net [+] | 0.2 | -12.0 | -3.0 | -2.5 | 2.3 | -0.2 | -3.0 | 0.0 |
| Gain (loss) on debt retirement | | -10.3 | -2.1 | -0.4 | | | -3.0 | |
| Other | 0.2 | -1.7 | -0.8 | -2.0 | 2.3 | -0.2 | 0.0 | 0.0 |
| Pre-tax income | -233.9 | -302.9 | -48.6 | -346.2 | 51.1 | 0.6 | 62.2 | 227.4 |
| Income taxes | -2.3 | 60.6 | -15.3 | -74.1 | 22.4 | 1.1 | 17.3 | 77.4 |
| Tax rate | 1.0% | | 31.4% | 21.4% | 43.8% | 199.5% | 27.9% | 34.0% |
| Minority interest | | | | | | 0.0 | 0.1 | 0.1 |
| Net income | -231.6 | -363.5 | -33.4 | -272.1 | 28.7 | -0.6 | 44.8 | 149.9 |
| Net margin | -68.0% | -75.9% | -6.1% | -41.5% | 4.2% | -0.1% | 8.3% | 36.8% |
| |
| Basic EPS [+] | ($5.74) | ($9.23) | ($0.86) | ($7.20) | $0.77 | ($0.02) | $1.23 | $4.18 |
| Growth | -37.8% | 967.3% | -88.0% | -1032.1% | -4996.2% | -101.3% | -70.6% | 146.7% |
| Diluted EPS [+] | ($5.74) | ($9.23) | ($0.86) | ($7.20) | $0.75 | ($0.02) | $1.20 | $4.04 |
| Growth | -37.8% | 967.3% | -88.0% | -1058.0% | -4863.4% | -101.3% | -70.3% | 148.9% |
| |
| Shares outstanding (basic) [+] | 40.4 | 39.4 | 38.6 | 37.8 | 37.1 | 36.8 | 36.4 | 35.8 |
| Growth | 2.4% | 2.1% | 2.2% | 1.8% | 0.9% | 1.0% | 1.7% | 6.4% |
| Shares outstanding (diluted) [+] | 40.4 | 39.4 | 38.6 | 37.8 | 38.2 | 36.8 | 37.4 | 37.1 |
| Growth | 2.4% | 2.1% | 2.2% | -1.0% | 3.7% | -1.5% | 0.7% | 5.5% |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |